To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
November 5, 2009 > First use of an antibody to deliver targeted radiation to leukemia patients
John M. Pagel, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘05-‘10) of the Fred Hutchinson Cancer Research Center, Seattle, reported the success of a Phase I clinical trial testing a novel combination of low-intensity chemotherapy, targeted radiation delivery by an antibody and a stem cell transplant. This regimen resulted in remission for patients with advanced acute myeloid leukemia or a pre-leukemia syndrome. These are patients for whom there previously had been no other treatment options. The report was published in the journal Blood.